Hot Topic Debate - Letermovir and Maribavir for CMV in Pediatric Transplant Recipients ? Game Changers or Just New Tools? (ATC 2026) - Jun 17, 2026 - Pres time: Jun 22, 2026; 01:45 PM - 02:45 PM; Location: 205BC' Level 2; "a.Standard prophylaxis and treatment strategies for cytomegalovirus (CMV) in pediatric solid organ transplant recipients (SOTR) have relied on inhibitors of DNA phosphorylase – ganciclovir (GCV) and valganciclovir (VGCV). Review of recent data will be embedded in the discussion and presented to set the stage. f.Suggested debates:i."Foscarnet should be replaced by maribavir for treatment of refractory cytomegalovirus infection in children with solid organ transplant"ii."Letermovir is reasonable primary prophylaxis for CMV in pediatric organ transplant recipients <12yo for whom GCV and VCGV are not an option"iii."Data from maribavir prophylaxis studies in adult stem cell recipients suggest this is not a viable agent for prophylaxis in immunocompromised hosts" TypesHot Topic Debate TopicsInfectious Disease KeywordsCytomeglovirus Infection Pediatric Viral therapy"
Clinical • Cytomegalovirus Infection • Infectious Disease • Pediatrics • Solid Organ Transplantation • Transplantation
|